menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

First-in-class, one-year data demonstrate sustained TTR protein reduction of approximately 97 percent, corresponding to 70 percent liver editing, following a single in vivo systemic dose in mice Non-human primate studies ongoing and leading to development candidate designation in first half 2018
Read More

Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences

CAMBRIDGE, Mass. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare conferences.
Read More

 Intellia Therapeutics Announces Second Quarter 2017 Financial Results

In non-human primates, demonstrated robust green fluorescent protein expression throughout the liver 24 hours following a single, systemically delivered, intravenous dose, using our proprietary lipid nanoparticle delivery system Using our proprietary lipid nanoparticle delivery system, demonstrated
Read More

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence
Read More

Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee

CAMBRIDGE, Mass. , July 24, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced today the appointment of Moncef Slaoui , Ph.D. and Frank Verwiel , M.D.
Read More

Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

Patent covers CRISPR/Cas9 gene editing methods and compositions for use in any setting, including human and other eukaryotic cells CAMBRIDGE, Mass. , June 19, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially
Read More

Intellia’s Response to Nature Methods Article on CRISPR/Cas9

To The Editor: Recently Schaefer et al . (1) reported the presence of more than a thousand genome differences between mice that had been edited with S. pyogenes Cas9 at the zygote stage, and a control mouse of the same strain. Given the overlap of genetic differences between the two edited mice
Read More

Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer

Research collaboration harnesses powerful CRISPR/Cas9 genome editing to engineer improved T-cell therapies targeting unmet needs in cancer Agreement builds on Intellia’s ex vivo approach through its division, eXtellia CAMBRIDGE, Mass. , and MILAN, Italy , June 06, 2017 (GLOBE NEWSWIRE) -- Intellia
Read More

Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat models First to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in serum transthyretin
Read More

Intellia Therapeutics Announces First Quarter 2017 Financial Results

First to demonstrate single dose, in vivo results using a proprietary lipid nanoparticle delivery system showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable
Read More
RSS FEEDS
PRINT PAGE